Skip to main navigation Skip to search Skip to main content

Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy

  • Andrea Chiricozzi*
  • , M. V. Cannizzaro
  • , G. A. Salandri
  • , B. Marinari
  • , R. Pitocco
  • , A. Dattola
  • , F. Regine
  • , R. Saraceno
  • , L. Bianchi
  • , S. Chimenti
  • , A. Costanzo
  • *Corresponding author
  • University of Rome Tor Vergata
  • University of Rome La Sapienza

Research output: Contribution to journalArticle

Abstract

Not available
Original languageEnglish
Pages (from-to)e128-e129
JournalJournal of the European Academy of Dermatology and Venereology
Volume30
DOIs
Publication statusPublished - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 2708
  • Adalimumab
  • Anti-Inflammatory Agents
  • Humans
  • Infectious Diseases
  • Interleukin-17
  • Psoriasis
  • Severity of Illness Index
  • Tears

Fingerprint

Dive into the research topics of 'Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy'. Together they form a unique fingerprint.

Cite this